Researchers find a way to delay Alzheimer's symptoms. But they have to prove it
An experimental treatment appears to delay Alzheimer’s symptoms in some people genetically destined to get the disease in their 40s or 50s, according to new findings from ongoing research now caught up in Trump administration funding delays. “This trial is life.” Two drugs sold in the U.S. can modestly slow worsening of early-stage Alzheimer’s by clearing the brain of one of its hallmarks, a sticky gunk called amyloid. Despite the study’s small size, “it’s incredibly important,” said Northwestern University neuroscientist David Gate, who wasn’t involved with the research. “Will they ever get the symptoms of Alzheimer’s disease if we keep treating them?” Here’s the worry: Bateman raised money to start that confirmatory study while seeking National Institutes of Health funding for the full project but his grant has been delayed as required reviews were canceled. For now, amyloid clearly is implicated somehow and families with Alzheimer’s-causing genes are helping answer a critical question for anyone at risk: Can blocking amyloid buildup really stave off symptoms?
FDA advisers strongly back new Alzheimer’s drug, despite risks and limitations
Study: Alzheimer's drug shows modest success slowing declines in memory, thinking
New Markers For Alzheimer's Disease Could Aid Diagnosis And Speed Up Drug Development
One of the most promising drugs for Alzheimer’s disease fails in clinical trials
Discover Related
Doctor Behind Award-Winning Parkinson’s Research Among Scientists Purged From NIH
Trump’s FDA Cuts Are Putting Drug Development at Risk
Two drugs prove to be effective against Alzheimer's disease in new study
NIH funding freeze stalls applications on $1.5 billion in medical research funds
Column: Trump’s assault on science will make Americans dumber and sicker
Australian researchers in limbo amid Trump's proposed funding cuts to health agency
'Dark time ahead': Scientists sound alarm at Trump's 'spiteful and targeted' cuts
Scientists Warn Trump's NIH Cuts Will Drop 'Atomic Bomb' On Health Research
The scientific fight over whether aging is a disease
New blood test could tell if you'll get Alzheimer's years from now
Why Alzheimer’s scientists are rethinking the amyloid hypothesis
Alzheimer’s Drugs Eyed by Investors Seeking Obesity-Like Gains
Weight-loss jab Ozempic 'could help patients with advanced Alzheimer's', scientists say
Could Texas do for Alzheimer’s research what it did for cancer?
With Trump coming into power, the NIH is in the crosshairs
Alzheimer's timeline shows changes start as trickle, become torrent
Opinion: Too many older Americans are getting tested for Alzheimer’s